Antifungal medication use through 180 days posttransplantation
| . | Fluconazole (N = 295) . | Voriconazole (N = 305) . |
|---|---|---|
| No. of days on study drug [IQR]* | 91 [27, 100] | 96 [34, 101] |
| Empiric antifungal therapy,† n (day 180 cumulative incidence) [95% CI] | 89 (30.2%) [24.9%, 35.5%] | 73 (24.1%) [19.2%, 29.0%] |
| Start day of empiric antifungal therapy median, [IQR] | 16 [10, 33] | 12 [8, 39] |
| Duration in days of empiric antifungal therapy median, [IQR]‡ | 7 [4, 17] | 7 [5, 15] |
| Premature withdrawal of study drug | ||
| Protocol-specified reason, n (%) | 103 (34.9%) | 109 (35.7%) |
| Nonprotocol-specified reason, n (%) | 28 (9.5%) | 15 (4.9%) |
| Total N (%) | 131 (44.4%) | 124 (40.7%) |
| Time (days) to premature withdrawal median, [IQR] | 29 [19, 54] | 29 [19, 58] |
| Unblinded use of antifungal prophylaxis, n (%) | ||
| Fluconazole only | 33 (11.2%) | 61 (20.0%) |
| Voriconazole only | 7 (2.4%) | 13 (4.3%) |
| Other mold-active agents | 16 (5.4%) | 22 (7.2%) |
| Total§ of voriconazole plus other antimold agents N (day 180 cumulative incidence) [95% CI] | 23 (7.8%) [4.7%, 10.9%] | 35 (11.5%) [8.0%, 15.0%] |
| Time (days) to unblinded use of antifungal prophylaxis median, [IQR] | 43 [22, 109] | 60 [22, 117] |
| . | Fluconazole (N = 295) . | Voriconazole (N = 305) . |
|---|---|---|
| No. of days on study drug [IQR]* | 91 [27, 100] | 96 [34, 101] |
| Empiric antifungal therapy,† n (day 180 cumulative incidence) [95% CI] | 89 (30.2%) [24.9%, 35.5%] | 73 (24.1%) [19.2%, 29.0%] |
| Start day of empiric antifungal therapy median, [IQR] | 16 [10, 33] | 12 [8, 39] |
| Duration in days of empiric antifungal therapy median, [IQR]‡ | 7 [4, 17] | 7 [5, 15] |
| Premature withdrawal of study drug | ||
| Protocol-specified reason, n (%) | 103 (34.9%) | 109 (35.7%) |
| Nonprotocol-specified reason, n (%) | 28 (9.5%) | 15 (4.9%) |
| Total N (%) | 131 (44.4%) | 124 (40.7%) |
| Time (days) to premature withdrawal median, [IQR] | 29 [19, 54] | 29 [19, 58] |
| Unblinded use of antifungal prophylaxis, n (%) | ||
| Fluconazole only | 33 (11.2%) | 61 (20.0%) |
| Voriconazole only | 7 (2.4%) | 13 (4.3%) |
| Other mold-active agents | 16 (5.4%) | 22 (7.2%) |
| Total§ of voriconazole plus other antimold agents N (day 180 cumulative incidence) [95% CI] | 23 (7.8%) [4.7%, 10.9%] | 35 (11.5%) [8.0%, 15.0%] |
| Time (days) to unblinded use of antifungal prophylaxis median, [IQR] | 43 [22, 109] | 60 [22, 117] |